Canada markets close in 3 hours 23 minutes

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0612+0.0006 (+0.96%)
As of 11:09AM EDT. Market open.

Entheon Biomedical Corp.

3030 Lincoln Avenue
Suite 211
Coquitlam, BC V3B 6B4
604 562 3932

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy KoPres, CEO & DirectorN/AN/A1985
Mr. Brandon Schwabe C.P.A., CGAChief Financial OfficerN/AN/A1987
Dr. Andrew Peter Hegle Ph.D.Chief Science Officer, Director of Operations & DirectorN/AN/A1978
Dr. Brian E. Jahns Pharm.D.Chief Bus. OfficerN/AN/AN/A
Ms. Kelly PladsonCorp. Sec.N/AN/A1983
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Entheon Biomedical Corp., a biotechnology research and drug development company, engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company is headquartered in Coquitlam, Canada.

Corporate Governance

Entheon Biomedical Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.